Tag Archives: ORMP

A Director at Oramed Pharmaceuticals (NASDAQ: ORMP) is Buying Shares

Yesterday, a Director at Oramed Pharmaceuticals (ORMP – Research Report), Leonard Sank, bought shares of ORMP for $4,250. See today’s analyst top recommended stocks >> Based on Oramed Pharmaceuticals’ latest earnings report for the quarter ending May 31, the company

Analysts Offer Insights on Healthcare Companies: Oramed Pharmaceuticals (NASDAQ: ORMP) and Durect Corp (NASDAQ: DRRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oramed Pharmaceuticals (ORMP – Research Report) and Durect Corp (DRRX – Research Report) with bullish sentiments. Oramed Pharmaceuticals (ORMP) H.C. Wainwright analyst

Oramed Pharmaceuticals (ORMP) Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals (ORMP – Research Report), with a price target of $25. The company’s shares closed on Friday at $4.15. Selvaraju observed: “Valuation methodology, risks

Oramed Pharmaceuticals (ORMP) Gets a Hold Rating from B.Riley FBR

B.Riley FBR analyst Andrew D’silva maintained a Hold rating on Oramed Pharmaceuticals (ORMP – Research Report) yesterday and set a price target of $5. The company’s shares opened today at $3.50, close to its 52-week low of $2.97. D’silva said:

Oramed Pharmaceuticals (ORMP) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (NASDAQ: ORMP) today and set a price target of $25. The company’s shares closed yesterday at $4.70, close to its 52-week low of $4.60. Selvaraju wrote: “Valuation methodology,

H.C. Wainwright Thinks Oramed Pharmaceuticals’ Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oramed Pharmaceuticals (NASDAQ: ORMP) today and set a price target of $25. The company’s shares closed on Friday at $4.87, close to its 52-week low of $4.60. Selvaraju wrote: “Valuation